7,156 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by Meeder Asset Management Inc.

Meeder Asset Management Inc. bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, HoldingsChannel reports. The firm bought 7,156 shares of the biopharmaceutical company’s stock, valued at approximately $4,462,000.

Several other large investors have also recently bought and sold shares of REGN. WPG Advisers LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 25 shares during the last quarter. Western Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals during the first quarter worth $26,000. SHP Wealth Management acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $26,000. Titan Wealth CI Ltd acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $29,000. Finally, Kemnay Advisory Services Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $31,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $810.24 on Wednesday. The company’s 50 day simple moving average is $683.57 and its 200 day simple moving average is $714.66. The stock has a market capitalization of $83.42 billion, a price-to-earnings ratio of 20.03, a price-to-earnings-growth ratio of 1.37 and a beta of 0.21. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. Regeneron Pharmaceuticals, Inc. has a 1 year low of $541.00 and a 1 year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping the consensus estimate of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $12.81 earnings per share. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Tuesday, August 18th. Regeneron Pharmaceuticals’s payout ratio is 9.29%.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Leerink raises price target: Leerink Partners increased its REGN price target from $641 to $824, implying modest additional upside. However, the firm retained a “market perform” rating, suggesting limited conviction in a stronger near-term advance. Benzinga analyst price target report
• Neutral Sentiment: Class-action deadline approaches: Several law firms, including Pomerantz, Hagens Berman, Faruqi & Faruqi, and The Schall Law Firm, reminded investors of a September 14, 2026 deadline to seek lead-plaintiff status in a securities lawsuit. These announcements largely repeat previously reported information and do not represent a new financial or regulatory finding. Pomerantz investor alert
• Negative Sentiment: Litigation highlights clinical-trial concerns: The lawsuits allege that Regeneron made misleading statements about clinical differentiation and slowing event accrual in the Phase 3 fianlimab-Libtayo study, potentially understating the risk that the trial would miss its primary endpoint. The trial failure reportedly erased roughly $11 billion in market value and could create ongoing legal costs, reputational risk, and uncertainty around the program’s commercial prospects. The allegations have not been proven. Hagens Berman Regeneron class-action notice

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Leerink Partners boosted their price target on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a research report on Monday. Royal Bank Of Canada increased their price target on Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a “sector perform” rating in a research note on Friday, July 31st. Wells Fargo & Company lifted their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a research report on Friday, July 31st. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective on the stock in a report on Tuesday, July 7th. Finally, HSBC dropped their price objective on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. Sixteen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $801.70.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $320,000.00. Following the transaction, the director owned 603 shares in the company, valued at approximately $482,400. The trade was a 39.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the transaction, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 1,400 shares of company stock worth $1,090,030. Company insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.